
### PATENT COOPERATION TREATY

### From the INTERNATIONAL BUREAU

### PCT

NOTIFICATION OF TRANSMITTAL
OF COPIES OF TRANSLATION
OF THE INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY
(CHAPTER I OR CHAPTER II
OF THE PATENT COOPERATION TREATY)

(PCT Rules 44bis.3(c) and 72.2)



Date of mailing (day/month/year)
02 March 2006 (02.03.2006)

Applicant's or agent's file reference
1548

International application No.
PCT/JP2004/004611

Applicant

KYOWA HAKKO KOGYO CO. LTD. et al

1.	Transmittal	of the	translation	to	the appl	licant.
1.	1 i ansimitai	or me	ti alisiauon	w	me app	ucant

<b>✓</b>	The International Bureau transmits herewith a copy of the English translation of the internatio	nal preliminary report or
ت ا	patentability (Chapter I).	

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter II).

Transmittal of the copy of the translation to the designated or elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following designated or elected Offices requiring such translation:

None

The following designated or elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AE, AG, AL, AM, AP, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EA, EC, EE, EG, EP, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OA, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability (Chapter II).

It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned within the applicable time limit (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Yoshiko Kuwahara

Facsimile No.+41 22 338 90 90

Facsimile No.+41 22 740 14 35 Form PCT/IB/338 (January 2004)

### PATENT COOPERATION TREATY

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference 1548	FOR FURTHER ACTION	See item 4 below				
International application No. PCT/JP2004/004611	International filing date (day/month/year) 31 March 2004 (31.03.2004)	Priority date (day/month/year) 31 March 2003 (31.03.2003)				
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237						
Applicant KYOWA HAKKO KOGYO CO. LTD.						

1.	This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).							
2.	This REPORT consists of a total of 6 sheets, including this cover sheet.							
	In the attached sheets, any refer to the international preliminary	ence to the written opinion of the International Searching Authority should be read as a reference report on patentability (Chapter I) instead.						
3.	This report contains indications	relating to the following items:						
	Box No. 1	Basis of the report						
	Box No. II	Priority						
	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
	Box No. IV	Lack of unity of invention						
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
	Box No. VI	Certain documents cited						
·	Box No. VII	Certain defects in the international application						
	Box No. VIII	Certain observations on the international application						
4.	The International Bureau will cont, except where the applicant date (Rule 44bis.2).	ommunicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but makes an express request under Article 23(2), before the expiration of 30 months from the priority						
	uate (Rule 440ts .2).							

	Date of issuance of this report 22 February 2006 (22.02.2006)
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer  Yoshiko Kuwahara
Facsimile No. +41 22 740 14 35	Telephone No. +41 22 338 90 90

Form PCT/IB/373 (January 2004)

#### PATENT COOPERATION TREATY

Pranslation From the INTERNATIONAL SEARCHING AUTHORITY PCT WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) Applicant's or agent's file reference FOR FURTHER ACTION 1548 See paragraph 2 below International filing date (day/month/year) Priority date (day/month/year) International application No. 31.03.2003 PCT/JP2004/004611 31.03.2004 International Patent Classification (IPC) or both national classification and IPC Applicant KYOWA HAKKO KOGYO CO. LTD. This opinion contains indications relating to the following items: Box No. I Basis of the opinion Box No. II Priority Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Certain observations on the international application FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Name and mailing address of the ISA/JP Authorized officer Facsimile No. Telephone No.

International application No.
PCT/JP2004/004611

Box	No. I	Basis of th	is opinion	•	•	-							
1.		regard to the language, unless otherwise in			n establish	ed on the l	pasis of the	internati	onal app	lication	in the la	inguage in	which it was
		This opinion has b	een establishe				-	_	_		_		norch (under
	-	Rule 12.3 and 23.	l(b)).	, which	n is the lang	guage of a	translation		a tor the	purpose	s or the	rnational sc	earch (under
2.	With inver	regard to any <b>nu</b> ntion, this opinion h	cleotide and/o	or amino a	icid seque basis of:	nce disclo	sed in the	internati	onal app	olication	and ne	cessary to	the claimed
	a.	type of material								ė			
		a sequence l	isting										
		table(s) relat	ed to the seque	ence listing									
	b.	format of material											
		in written fo	rmat	,									
	·	in computer	readable form										
	c.	time of filing/furn	ishing										
		contained in	the internation	nal applicat	ion as filed	•						•	
		filed togethe	er with the inte	rnational ap	plication is	n computer	r readable 1	form.			٠		
		furnished su	bsequently to	this Author	ity for the p	ourposes of	f search.						
3.		In addition, in the furnished, the required or does not g	uired statemen	ts that the i	nformation	in the sub	sequent or	additiona	nd/or tal	ble(s) re is ident	elating the	hereto has l hat in the a	been filed or pplication as
4.	Addi	itional comments:											
										•			
					**	-			e •	•			φ.
			•			•							
•					•		•		•				
		•											
												•	

International application No.
PCT/JP2004/004611

Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
	ons whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially have not been examined in respect of:
	the entire international application
	claims Nos. 4-6
	the said international application, or the said claims Nos. 4-6 relate to the following subject matter which does not require an international preliminary examination (specify):
	The inventions of claims 4-6 concern treating the human body by therapy (PCT Article 34
	(4)(a)(i) and PCT Rule 67.1(iv).
50	
	the description, claims or drawings (indicate particular elements below) or said claims Nos.  are so unclear that no meaningful opinion could be formed (specify):
<u> </u>	
	the claims, or said claims Nos are so inadequately supported by the description that no meaningful opinion could be formed.
$\boxtimes$	no international search report has been established for said claims Nos. 4-6
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:
	the written form has not been furnished
	does not comply with the standard
	the computer readable form has not been furnished does not comply with the standard
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the
	technical requirements provided for in Annex C-bis of the Administrative Instructions.  See Supplemental Box for further details.
1	

International application No. PCT/JP2004/004611

Box			ule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; pporting such statement	
1.	Statement			
	Novelty (N)	Claims	1-3, 7-9	YES
	•	Claims		NO
	, Inventive step (IS)	Claims		YES
		Claims	1-3, 7-9	NO
	Industrial applicability (IA)	Claims	1-3, 7-9	YES
		Claims		NO
i			<b>.</b>	

#### 2. Citations and explanations:

The opinion in this report is based on the following documents cited in the international search report.

Document 1: WO 96/36624 A1 (Kyowa Hakko Kogyo Co., Ltd.) & EP 771794 A1 Document 2: WO 03/016279 A1 (Tanabe Seiyaku Co., Ltd.) & EP 1424326 A1

Document 3: WO 02/098880 A1 (BAYER AKTIENGESELLSCHAFT)

Document 4: JP 2002-537383 A (Merck Frosst Canada & Co.) & EP 1157007 A1 Document 5: WO 00/51598 A1 (SMITHKLINE BEECHAM CORPORATION)
Document 6: Masayoshi ISHIBASHI et al., Gendai Iryo, 2002, 34(9), pp. 2249-2254

Document 7: Naomi YAMASHITA, Biomedicine & Therapeutics, 2001, 35(11), pp. 1225-1226

Document 8: Yukio NAGASAKA, Kokyu to Junkan, 1996, 44(8), pp. 839-845

Document 9: HAEFNER, D., et al., Am. J. Respir. Crit. Care Med., 2000 161, pp. 1495-1500

Document 10: TEIXEIRA, M.M., et al., TiPS, 1997, (18), pp. 164-170

#### oClaims 1-3 and 7-9

Document 1 (Example 140) describes a compound that has PDE4 inhibitory activity and has the structure represented by Formula (I) of this application, and the specification (page 1, line 4 to page 3, line 23) describes the use of that compound as a medicine. This being the case, when we compare the inventions of claims 1-3 and 7-9 with the invention described in document 1, the former differs from the latter because its application is the treatment of pulmonary diseases associated with neutrophilic inflammation, and more specifically, COPD, ARDS, etc.

However, it is publicly known from documents 2-9 that ingredients that have PDE4 inhibitory activity are useful in the treatment of COPD and lung tumors, and from documents 2-4, 9, and 10 that such ingredients are useful in the treatment of ARDS and acute lung trauma. Moreover, as described in documents 3 and 5-8, it is publicly known that these diseases are associated with neutrophilic inflammation. Thus, this examination finds that persons skilled in the art would require no particular ingenuity to use the compound that has PDE4 inhibitory activity and has the structure represented by Formula (I) of this application described in document 1 for the prevention and treatment of COPD, ARDS, etc.

As a result, based on the descriptions in documents 1-10, the inventions of claims 1-3 and 7-9 lack an inventive step.

International application No.
PCT/JP2004/004611

Box No. VI Certain documents cited	<u> </u>		
1. Certain published documents (Rule 43bis.1 and	70.10)	*	
Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
WO 03/066044 A1 [EY]	14.08.2003	31.01.2003	08.02.2002
WO 2004/005276 A1 [EY]	15.01.2004	03.07.2003	03.07.2002
WO 03/080049 A1 [EY]	02.10.2003	20.03.2003	20.03.2002 07.01.2003

2.	Non-written disclosures (Rule 43bis.1 and 70.9)	•	
		·	Date of written disclosure
	Kind of non-written disclosure	Date of non-written disclosure	referring to non-written disclosure
		(day/month/year)	(day/month/year)